NCT03166618 is a NA clinical trial of Juvéderm® VOLUMA XC in Temple Hollowing, sponsored by Allergan.

Who is sponsoring NCT03166618?

NCT03166618 is sponsored by Allergan.

What drugs are being tested in NCT03166618?

Interventions in NCT03166618: Juvéderm® VOLUMA XC.

What condition does NCT03166618 study?

NCT03166618 studies Temple Hollowing.

Is NCT03166618 still recruiting?

NCT03166618 is currently terminated. Last updated 18 October 2018.

Are results published for NCT03166618?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2018-10-18 · How we verify

NCT03166618

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Safety and Effectiveness of JUVÉDERM VOLUMA® XC Injectable Gel for Correction of Temple Hollowing

Terminated NA Results posted Last updated 18 October 2018

What this trial tests

NA trial testing Juvéderm® VOLUMA XC in Temple Hollowing in 1 participant. Terminated before completion.

Timeline

24 April 2017

Primary endpoint
21 July 2017

21 July 2017

Quick facts

Lead sponsor	Allergan
Phase	NA
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	1
Start date	24 April 2017
Primary completion	21 July 2017
Estimated completion	21 July 2017
Sites	1 location across United States

Drugs / interventions tested

Juvéderm® VOLUMA XC

Conditions studied

Temple Hollowing — all drugs for Temple Hollowing →

Sponsor

Allergan — full company profile →

Who can join

22 and older, any sex, with Temple Hollowing. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will evaluate the safety and effectiveness of JUVÉDERM VOLUMA XC injectable gel in adult participants seeking correction of temple hollowing.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Temple Hollowing

Currently open trials in the same condition.

NCT06972940 — A Prospective, Multicenter, Randomized, No-treatment Controlled, Assessor-blinded, Superiority Clinical Trial to Evaluat · NA · recruiting

Other Allergan trials

Trials by the same sponsor.

NCT04609020 — Study to Evaluate Subject Satisfaction With Facial Appearance and Impact of Combined Facial Treatment · Phase 4 · completed
NCT05452070 — A Study to Assess Adverse Events and Change in Disease Activity of HArmonyCa Lidocaine Injectable Gel for Mid Face Soft · Phase 3 · completed
NCT05393089 — Study of AGN-190584 Eye Drops to Assess Safety and Efficacy in Participants Aged 40-80 Years With Pseudophakic Presbyopi · Phase 2 · withdrawn
NCT05152576 — A Study To Assess the Adverse Effects and Change in Condition of OnabotulinumtoxinA X Injection in Adult Participants Wi · Phase 2 · completed
NCT05088980 — Study to Assess Effectiveness and Adverse Events of JUVEDERM VOLBELLA With Lidocaine Injection in Correcting Infraorbita · Phase 3 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03166618 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Allergan
Last refreshed: 18 October 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03166618.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing